EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program

EXACT Therapeutics AS

Oslo, Norway, 11 February 2026. Reference is made to the stock exchange
announcement published 6 February 2026 by EXACT Therapeutics AS (the "Company",
Euronext Growth ticker: EXTX), regarding the global investor call to be held in
conjunction with the ongoing warrants exercise program.

As a reminder, the Company will host a global investor call (in English) today,
Wednesday, 11 February 2026 at 3 PM CET / 9:00 AM EST. The presentation will be
held by the Company's CEO, Per Walday; CFO, John M. Edminson; and CBO, Caspar
Foghsgaard. Please find attached a copy of the presentation that will be
presented. The presentation will also be made available in the Investors section
of the Company's website.

To attend the webcast, please send an email to: ca@dnbcarnegie.no.

About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX).


Further information may be found here: www.exact-tx.com

For further information, please contact:
Per Walday CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

665373_260211 EXACT Therapeutics - global inv call - final.pdf